<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03353259</url>
  </required_header>
  <id_info>
    <org_study_id>2016/1512/REK nord</org_study_id>
    <secondary_id>2017-001670-42</secondary_id>
    <nct_id>NCT03353259</nct_id>
  </id_info>
  <brief_title>Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery</brief_title>
  <official_title>Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objectives of the study are to investigate whether adjuvant treatment in the form of
      Tranexamic acid (Cyklokapron) and Tocilizumab (RoAcmera) to surgery in patients with chronic
      subdural hematomaina can:

        1. effectively decrease the rate of lesion recurrence requiring re-operation,

        2. effectively shorten the time of lesion resolution.

      Secondary objectives of the study are:1) assess the postoperative functional outcome and
      quality of life of participants, 2) assess the postoperative mortality of participants, 3)
      assess the treatment safety data, 4) assess the cure rate of participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoints in the study are: 1) determine postoperative recurrence requiring
      reoperation using clinical examination and CT imaging, 2) determine the time period necessary
      to complete healing using clinical examination and CT imaging.

      Secondary endpoints in the study are: 1) to determine the functional outcome and quality of
      life of the participants using questionnaires, 2) to determine the mortality of the
      participants related to chronic subdural hematoma, 3) to determine the treatments
      complications and adverse events of the participants, 4) to determine the curation using
      clinical examination and CT imaging.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Tocilizumab (RoActemra) and Tranexamic acid (Cyklokapron) used as Adjuncts to Chronic Subdural Hematoma Surgery Regarding Postoperative Recurrence</measure>
    <time_frame>6 months period after the initial surgery.</time_frame>
    <description>To determine the rate in number and percentage of postoperative recurrence requiring re-operation</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Chronic Subdural Hematoma</condition>
  <arm_group>
    <arm_group_label>SS-TG</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard surgery using burr-hole procedure, irrigation and drainage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SS-TXA-TG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard surgery using burr-hole procedure, irrigation and drainage combined withTranexamic acid (Cyklokapron) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day until complete hematoma disappearance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SS-TXA-RoA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard surgery using burr-hole procedure, irrigation and drainage combined with Tranexamic acid (Cyklokapron) and Tocilizumab (RoActemra) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day combined with RoActemra subcutaneous injection of 162 mg once a week until complete hematoma disappearance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Tranexamic acid and Tocilizumab</intervention_name>
    <description>The first intervention is Tranexamic acid, The second intervention is Tocilizumab</description>
    <arm_group_label>SS-TXA-TG</arm_group_label>
    <arm_group_label>SS-TXA-RoA</arm_group_label>
    <other_name>Cyklokapron and RoActemra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with informed consent, without presenting of any known contraindication for
             the use of Tranexamic acid and Tocilizumab.

        Exclusion Criteria:

          -  patients or relatives who refused to consent, presenting of any known contraindication
             for the use of Tranexamic acid and Tocilizumab.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milo Stanisic</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Milo Stanisic, DrMedSci</last_name>
    <phone>+47 93932382</phone>
    <email>mstanisi@ous-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Milo Stanisic</last_name>
    <phone>+47 93932382</phone>
    <email>mstanisi@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Milo Stanisic</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milo Stanisic, DrMedSci</last_name>
      <phone>+4793932382</phone>
      <email>mstanisi@ous-hf.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2017</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Milo Stanisic</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma</mesh_term>
    <mesh_term>Hematoma, Subdural</mesh_term>
    <mesh_term>Hematoma, Subdural, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

